Science News

... from universities, journals, and other research organizations

Activation Of Liver X Receptor-Beta Lowers Cholesterol And Reverses Atherosclerosis

ScienceDaily (July 26, 2007) — In animals and humans, the proteins known as liver X receptors (LXRs) sense cholesterol levels. Upon sensing increases in cholesterol, these receptors activate signaling pathways that remove diet-derived cholesterol from the body. Two types of LXRs – LXR-alpha and LXR-beta – are therefore potential targets for the development of anti-atherosclerosis drugs.

However, the effects of synthetic drugs that activate these two receptors have not been well studied.

In a study appearing online on July 26 in advance of publication in the August print issue of the Journal of Clinical Investigation, Peter Tontonoz and colleagues from the University of California, Los Angeles, show that activation of LXR-beta by a synthetic compound is able to reverse atherosclerosis and cholesterol overload in mice.

The authors began by studying mice lacking apolipoprotein E (apoE; a protein that functions in cholesterol distribution among cells), which have increased cholesterol levels and are predisposed to develop atherosclerosis. They showed that the loss of LXR-alpha in these animals results in a striking body-wide accumulation of cholesterol and accelerated atherosclerosis.

This observation suggests that LXR-beta alone is unable to maintain homeostasis under conditions of cholesterol overload. Surprisingly, however, administration of a synthetic compound that activates LXR-beta, was able to compensate for the loss of LXR-alpha, reduce cholesterol overload and reduce atherosclerosis.

The results of the study suggests that LXR-alpha has an essential role in maintaining cholesterol homeostasis in conditions of cholesterol overload such as hypercholesterolemia and lend support to the notion that future drug development studies should examine targeting LXR-beta.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

| More

Story Source:

The above story is reprinted from materials provided by Journal of Clinical Investigation, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


APA

MLA

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Search ScienceDaily

Number of stories in archives: 114,933

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

 
  more breaking science news

Social Networks


Recommend this story on Facebook, Twitter,
and Google +1:
Other bookmarking and sharing tools:
| More

Breaking News

... from NewsDaily.com

In Other News ...

Copyright Reuters 2008. See Restrictions.

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

 
Post this page to your favorite social bookmarking site:
close
Include this item in your blog or web site:
close
Cite this article in your essay, paper, or report:
close
Email this page's link to a friend or colleague:
close